Vivani Medical (NASDAQ:VANI – Get Free Report) and Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.
Earnings & Valuation
This table compares Vivani Medical and Cumberland Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivani Medical | N/A | N/A | -$26.61 million | ($0.35) | -3.93 |
| Cumberland Pharmaceuticals | $44.52 million | 2.58 | -$2.84 million | ($0.71) | -10.78 |
Risk and Volatility
Vivani Medical has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.
Institutional and Insider Ownership
6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 53.3% of Vivani Medical shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Vivani Medical and Cumberland Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivani Medical | N/A | -191.05% | -70.91% |
| Cumberland Pharmaceuticals | -34.40% | -28.81% | -9.25% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Vivani Medical and Cumberland Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivani Medical | 1 | 1 | 2 | 0 | 2.25 |
| Cumberland Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Vivani Medical currently has a consensus target price of $3.75, suggesting a potential upside of 172.53%. Given Vivani Medical’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vivani Medical is more favorable than Cumberland Pharmaceuticals.
Summary
Vivani Medical beats Cumberland Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
